MAF Test®
Clinical Evidence
Click on each event to open the supporting publication
Background: landmark trials in adjuvant breast cancer treatment
MAF Test® is a novel tool, backed by level 1B clinical evidence, with the potential to guide bisphosphonate use in adjuvant breast cancer
AZURE Trial: Effect of MAF Amplification on Adjuvant Zoledronic Acid Treatment Outcome in Early Breast Cancer Patients
Long Term Survival Benefits of Adjuvant Zoledronic
Acid Associated with MAF Status of Primary
Tumor
AZURE Trial: Benefits and Risks of Adjuvant Treatment with Zoledronic Acid (ZOL) in Stage II/III Breast Cancer
10-year follow-up outcomes improved with ZOL
in MAF(-) women
79% women with a MAF(-) tumor, ZOL improved
IDFS and OS irrespective of menopause status
ZOL did not improve disease outcomes in MAF(+) tumors
B-34 Trial: Benefits and Risks of Adjuvant Treatment with Clodronate (CLO) in Stage I/III Breast Cancer
MAF B-34 study confirms the findings
of MAF AZURE trial
Improved DFS and OS in MAF(-)
patients, independent of menopause status
CLO did not improve disease outcomes in MAF(+) tumors
MAF Gene Expression and Breast Cancer Bone Metastasis
May help identify patients who benefit from bisphosphonates
MAF Biomarker Discovery and effects on bone metastasis
AZURE Trial: Effect of MAF Amplification on Adjuvant Zoledronic Acid Treatment Outcome in Early Breast Cancer Patients
Benefit for MAF(-) independent of menopause status
MAF predicts benefit from adjuvant zoledronic acid, independent of menopause status
Bone Health in Cancer: ESMO Clinical Practice Guidelines
"MAF is a transcription factor that is amplified in around 20% of bone metastases has been shown in one study to predict disease benefits with zoledronate in those with normal MAF status and harm, especially in younger patients and in those with MAF (+) amplification. Validation of these results are awaited before this biomarker can be considered for routine use.”
NSABP B-34 MAF Confirmatory Study Abstract
Clodronate addition to adjuvant treatment increases
time to relapse and OS in MAF(-) tumors independent of menopausal status
Together, we will drive new perspectives towards a future where breast cancer is no longer a life-threatening disease.
